Drug-induced cholestasis

Bibliography

• CHITTURI S, FARRELL GC: Drug-Induced Liver Disease. In: Schiff's Diseases of the Liver (9th edr). Lippincott Williams & Wilkins, New York (2002):Chapter 38.
   Google Scholar
• •Article of interest for comprehensive coverage of recent causes of DILD.
   Google Scholar
• FARRELL GC: Liver disease due to drugs, anesthetics, and toxins. In: Sleisenger FordtrarLi Gastrointestinal and Liver Disease (7th edrl). Feldman M, Friedman LS, Sleisenger MH (Eds), Saunders, Philadelphia (2002):1403–1447.
   Google Scholar
• FARRELL GC: Drug-induced cholestasis. In: Drug-induced Liver Disease. Churchill Livingstone, Edinburgh (1994):319–369.
   Google Scholar
• KAPLOWITZ N: Biochemical and cellular mechanisms of toxic liver injury. Seraill. Liver Dis. (2002) 22:137–144.
   PubMed Web of Science ®Google Scholar
• •Article of interest for discussion of mechansisms of DILD.
   Google Scholar
• SGRO C, CLINARD F, OUAZIR K et al: Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology (2002) 36:451–455.
   PubMed Web of Science ®Google Scholar
• •Article of interest for discussion of frequency of ADRs affecting the liver.
   Google Scholar
• DEVEREAUX BM, CRAWFORD DH, PURCELL P, POWELL LW, ROESER HP: Flucloxacillin-associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur j Clin. Pharmacol (1995) 49:81–85.
   Web of Science ®Google Scholar
• DERBY LE, JICK H, HENRY DA, DEAN AD: Cholestatic hepatitis associated with flucloxacillin. Med. j Aust. (1993) 158:596–600.
   PubMed Web of Science ®Google Scholar
• GOSBELL IB, TURNIDGE JD, TAPSALL JW, BENN RAV: Toxicities of flucloxacillin and dicloxacillin - is there really a difference? Med. I Aust. (2000) 173:500. Letter.
   Google Scholar
• GEUBEL AP SEMPOUX CL: Drug- andtoxin-induced bile duct disorders. Gastroentorol Hepatol (2000) 15:1232–1238.
   PubMed Web of Science ®Google Scholar
• O'DONOHUE J, OIEN KA, DONALDSON P et al: Co-amoxyclav jaundice: clinical and histological features and HLA Class II association. Gut (2000) 47:717–720.
   PubMed Web of Science ®Google Scholar
• HAUTEKEETE ML, HORSMANS Y, WAEYENBERGE CV et al.: HLA association of amoxycillin-clavulanate-induced hepatitis. Gastroenterology (1999) 117:1181–1186.
   PubMed Web of Science ®Google Scholar
• KUROSAKI M, TAKAGI H, MORI M: HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig. Dis. ScL (2000) 45:1103–1118.
   PubMed Web of Science ®Google Scholar
• BERSON A, FRENEAUX E, LARREY D et al.: Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. Hepatol. (1994) 20:336–342.
   Google Scholar
• •Article of interest for discussion of genetic susceptibility to DILD.
   Google Scholar
• ISHAK KG, IREY NS: Hepatic injury associated with phenothiazines. Clinicopathologic and follow up study of 36 patients. Arch. Pathol (1972) 93:283–304.
   Google Scholar
• FAIRLEY CK, MCNEIL JJ, DESMOND P et al.: Risk factors for development of flucloxacillin-associated jaundice. Br. Med. (1993) 307:1179.
   Web of Science ®Google Scholar
• GRESSER U: Amoxycillin-clavulinic acid therapy may be associated with severe side effects - review of the literature. Bur. j Med. Res. (2001) 6:139–149.
   PubMed Web of Science ®Google Scholar
• HOKKANEN OT, SOTANIEMI EA: Liver injury and multiple drug therapy. Arch. Taxied. Suppl. (1978) 1:173–176.
   PubMedGoogle Scholar
• SMITH DW, CULLITY GJ, SILBERSTEIN EP: Fatal hepatic necrosis associated with multiple anticonvulsant therapy. Aust. NZ j Med. (1988) 18:575–581.
   PubMedGoogle Scholar
• PEREZ GUTTHANN S, GARCIA RODRIGUEZ LA: The increased risk of hospitalisations for acute liver injury in a population with exposure to multiple drugs. Epidemiology (1993) 4:496–501.
   PubMed Web of Science ®Google Scholar
• KNOWLES SR, UETRECHT J, SHEAR NH: Idiosyncratic drug reactions:the reactive metabolite syndromes. Lancet (2000) 356:1587–1591.
   PubMed Web of Science ®Google Scholar
• ••Article of considerable interest. This paperdescribes a very common pattern of ADRs that affects the liver, with implications for risk factors and prevention.
   Google Scholar
• ZIMMERMAN HJ: Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver (2nd edn) Lippincott Williams & Wilkins, Philadelphia (1999).
   Google Scholar
• TRAUNER M, METER PJ, BOYER JL: Molecular pathogenesis of cholestasis. N. Engl. J. Med. (1998) 339:1217–1227.
   PubMed Web of Science ®Google Scholar
• BOHAN A, BOYER JL: Mechanism of hepatic transport of drugs: implications for cholestatic drug reactions. Semil. Liver Dis. (2002) 22:123–136.
   PubMed Web of Science ®Google Scholar
• ••Article of considerable interest. Thispaper outlines mechanisms of drug-induced cholestasis.
   Google Scholar
• MOTTINO AD, CAO J, VEGGI LM, CROCENZI F, ROMA MC, VORE M: Altered localization and activity of canalicular MRP2 in estradio1-1713-D-glucuronide-induced cholestasis. Hepatology (2002) 35:1409–1419.
   PubMed Web of Science ®Google Scholar
• STIEGER B, FATTINGER K, MADON J, KULLAK-UBLICK GA, METER PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology (2000) 118:422–428.
   PubMed Web of Science ®Google Scholar
• FUNK C, PONELLE C, SCHEUERMANN G, PANTZE M: Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol (2001) 59:627–635.
   PubMed Web of Science ®Google Scholar
• PHAM B-N, BERNUAU J, DURAND F et al.: Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. j Hepatol (2001) 34:537–547.
   PubMed Web of Science ®Google Scholar
• BENICHOU C: Criteria of drug induced liver disorders: report of an international consensus meeting. I Hepatol (1990) 11:272–276.
   Web of Science ®Google Scholar
• BENICHOU C, DANAN G, FLAHAULT A: Causality assessment of adverse drug reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. j Clin. Epidemiol (1993) 46:1331–1336.
   Google Scholar
• •Article of interest. This paper discusses causality assessment.
   Google Scholar
• MARIA VAJ, VICTORINO RMM: Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology (1997) 26:664–669.
   PubMed Web of Science ®Google Scholar
• KAPLOWITZ N: Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology (2001) 33:308–310.
   PubMed Web of Science ®Google Scholar
• LUCENA MI, CAMARGO R, ANDRADE RJ, PEREZ-SANCHEZ CJ, DE LA CUESTA FS: Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology (1990) 11:123–130.
   PubMedGoogle Scholar
• DANAN G: Causality assessment of drug-induced liver injury. Hepatology working group. j Hepatol (1988) 7:132–136.
   PubMed Web of Science ®Google Scholar
• CHITTURI S, FARRELL GC: Drug-induced cholestasis. &min. Gastrointest. Dis. (2001) 12:113–124.
   PubMedGoogle Scholar
• •Article of interest. Recent review of DILD with respect to cholestatic reactions.
   Google Scholar
• LIEBERMAN DA, KEEFFE EB, STENZEL P: Severe and prolonged oral contraceptive jaundice. I OM. Gastroenterol (1984) 6:145–148.
   Web of Science ®Google Scholar
• HERRINE SK, CHOUDHARY C: Severe hepatotoxicity associated with troglitazone. Ann. Intern. Med. (1999) 130:163–164.
   PubMed Web of Science ®Google Scholar
• CHANG CC, PETRELLI M, TOMASHEFSKI JF, MCCULLOUGH AJ: Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch. Pathol Lab. Med. (1999) 123:251–256.
   PubMed Web of Science ®Google Scholar
• SOLIS-HERRUZO JA, CASTELLANO G, COLINA F et al: Hepatic injury in the toxic epidemic syndrome caused by ingestion of adulterated cooking oil (Spain 1981). Hepatology (1984) 4:131–139.
   PubMed Web of Science ®Google Scholar
• THOMPSON JP, CASEY PB, VALE JA: Deaths from pesticide poisoning in England and Wales 1990-1991. Hum. Exp. Taxied. (1995) 14:437–445.
   PubMed Web of Science ®Google Scholar
• LEONARDO B: Liver biopsy in elevatedliver functions test? An old question revisited. j Hepatol (2001) 35:290–294.
   PubMed Web of Science ®Google Scholar
• DEGOTT C, FELDMANN G, LARREY D et al: Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology (1992) 15:244–251.
   PubMed Web of Science ®Google Scholar
• •Article of interest. Discusses pathology of DILD and prognostic factors.
   Google Scholar
• AITHAL PG, DAY CP: The natural history of histologically-proved drug-induced liver disease. Gut (1999) 44:731–735.
   PubMed Web of Science ®Google Scholar
• ••Article of considerable interest. Discussesoutcomes of DILD.
   Google Scholar
• LASSO DE LA VEGA, ZAPATER E SUCH J et al.: [Toxic hepatitis associated with tamoxifen use. A case report and literature reviewl. Gastroenterol Hepatol (2002) 25:247-250. Spanish.
   Google Scholar
• BRAY GE TREDGER JM, WILLIAMS R: Resolution of danazol-induced cholestasis with S-adenosylmethionine. Postgrad. Med. (1993) 69:237–239.
   Google Scholar
• LINBERG MC: Hepatobiliary complications of oral contraceptives. Gen. Intern. Med. (1992) 7:199–209.
   PubMed Web of Science ®Google Scholar
• ORELLANA-ALCADE JM, DOMINGUEZ JP: Jaundice and oral contraceptive drugs. Lancet (1966) 2:1279–1280.
   PubMedGoogle Scholar
• METREAU JM, DHUMEAUX D, BERTHELOT P: Oral contraceptives and the liver. Digestion (1972) 7:318–335.
   PubMed Web of Science ®Google Scholar
• LABOWITZ JK, SILVERMAN WB: Cholestatic jaundice induced by ciprofloxacin. Dig. Dis. Sci. (1997) 42:192–194.
   PubMed Web of Science ®Google Scholar
• HAUTEKEETE ML, KOCKX MM, NAEGELS S, HUBENS H, KLOPPEL G: Cholestatic hepatitis related to quinolones: a report of two cases. j Hepatol (1995) 23:759–760.
   PubMed Web of Science ®Google Scholar
• YEW WW, CHAN CH, LEE J et al.: Cholestatic hepatitis in a patient who received clarithromycin therapy for Mycobacterium chelorrae lung infection. OM. Infect. Dis. (1994) 18:1025-1026. Letter.
   Google Scholar
• FOX JC, SCYJKOWSKI RS, SANDERSON SO, LEVINE RA: Progressive cholestatic liver disease associated with clarithromycin treatment. Pharmacol (2002) 42:676–680.
   Web of Science ®Google Scholar
• SURIAWINATA A, MIN AD: A 33-year-old woman with jaundice after azithromycin use. Semirr. Liver Dis. (2002) 22:207–210.
   PubMed Web of Science ®Google Scholar
• LONGO G, VALENTI C, GANDINI G et al.: Azithromycin-induced intrahepatic cholestasis. Am. j Med. (1997) 102:217–218.
   PubMed Web of Science ®Google Scholar
• BJORNSSON E, OLSSON R: Acute liver injury due to loracarbef. I Hepatol (1997) 26:739–740.
   Web of Science ®Google Scholar
• STRICKER BHC: Drug-induced hepatic injury Elsevier, Amsterdam (1992).
   Google Scholar
• LOK AS, NG 10: Prochlorperazine-induced chronic cholestasis. I Hepatol (1988) 6:369–373.
   Web of Science ®Google Scholar
• DINCSOY HP, SAELINGER DA: Haloperidol-induced chronic cholestatic liver disease. Gastroenterology (1982) 83:694–700.
   PubMed Web of Science ®Google Scholar
• SARFRAZ A, COOK M: Sulpiride-inducedcholestatic jaundice. Aust. NZ I Psychiatry (1996) 30:701–702.
   PubMed Web of Science ®Google Scholar
• NISSAN A, SPIRA RM, SEROR D, ACKERMAN Z: Captopril-associated 'pseudocholangitis'. A case report and review of the literature. Arch. Surg. (1996) 131:670–671.
   PubMed Web of Science ®Google Scholar
• CRANTOCK L, PRENTICE R, POWELL L: Cholestatic jaundice associated with captopril therapy. I Gastroenterol Hepatol (1991) 6:528–530.
   PubMed Web of Science ®Google Scholar
• ZIMRAN A, ABRAHAM AS, HERSHKO C: Reversible cholestatic jaundice and hyperamylasaemia associated with captopril treatment. Br. Med. I (1983) 287:1676.
   PubMed Web of Science ®Google Scholar
• SAHAI A, VILLENEUVE JP: Terbinafine-induced cholestatic hepatitis. Lancet (1996) 348:552–553.
   PubMed Web of Science ®Google Scholar
• IVERSON SL, UETRECHT JP: Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicty. Chem. Res. Taxied. (2001) 14:175–181.
   PubMed Web of Science ®Google Scholar
• LAZAROS GA, PAPATHEODORIDIS GV, DELLADETSIMA JK, TASSOPOULOS NC: Terbinafine-induced cholestatic liver disease. I Hepatol (1996) 24:753–756.
   Web of Science ®Google Scholar
• MALLAT A, ZAFRANI ES, METREAU JM, DHUMEAUX D: Terbinafine-induced prolonged cholestasis with reduction of interlobular ducts. Dig. Dis. Li. (1997) 42:1486–1488.
   PubMed Web of Science ®Google Scholar
• CHAMBERS WM, MILLAR A, JAIN S, BURROUGHS AK: Terbinafine-induced hepatic dysfunction. Eur. I Gastroenterol Hepatol (2001) 13:1115–1118.
   PubMed Web of Science ®Google Scholar
• BOELSTERLI UA: Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Sal (2002) 25:633–648.
   PubMed Web of Science ®Google Scholar
• VAN STEENBERGEN W, PEETERS P, DE BONDT J et al.: Nimesulide-induced acute hepatitis: evidence from six cases. Hepatol (2000) 32:174.
   PubMed Web of Science ®Google Scholar
• ANDRADE RJ, LUCENA MI, FERNANDEZ MC et al.: Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicty. Eur. I Gastroenterol Hepatol (2002) 14:887–890.
   PubMed Web of Science ®Google Scholar
• HARIRAJ R, STONER E, JADER S, PRESTON DM: Drug points: prolonged cholestasis associated with irbesartan. Br Med. J. (2000) 321:547.
   PubMed Web of Science ®Google Scholar
• ROSENBERG WM, RYLEY NG, TROWELL JM, MCGEE JO, CHAPMAN RW: Dextropropoxyphene-induced hepatotoxicity: a report of nine cases. I Hepatol (1993) 19:470–474.
   Web of Science ®Google Scholar
• BASSENDINE ME WOODHOUSE KW, BENNETT M, JAMES OF: Dextropropoxyphene-induced hepatotoxicity mimicking binary tract disease. Gut (1986) 27:444–449.
   PubMed Web of Science ®Google Scholar
• LEE TH, REES PJ: Hepatotoxicity of dextropoxyphene. Br. Med. 1 (1977) 30:296–297.
   Google Scholar
• KOPELMAN H, ROBERTSON MH, SANDERS PG et al: The Epping jaundice. Br Med. I (1966) 1:514–516.
   PubMed Web of Science ®Google Scholar
• FARRELL GC, WELTMAN M: Drug-induced liver disease. In: Current Hepatology (Vol. 16). Gitnick G (Ed.), Mosby, St Louis, MO (1996):143–208.
   Google Scholar
• COLLE I, REYNAERT HNAEGELS S et al.: Cinnarizine-induced cholestasis. I Hepatol (1999) 30:553.
   Google Scholar
• MORADPOUR D, ALTORFER J, FLURY R et al.: Chlorpromazine induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology (1994) 20:1437–1441.
   PubMed Web of Science ®Google Scholar
• DAVIES MH, HARRISON RF, ELIAS E, HUBSCHER SG: Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. I Hepatol (1994) 20:112–116.
   Web of Science ®Google Scholar
• OLSSON R, WILHOLM BE, SAND C, ZETTERGREN L, HULTCRANTZ R, MYRHED M: Liver damage from flucloxacillin, cloxacillin and dicloxacillin. Hepatol (1992) 15:154–161.
   Web of Science ®Google Scholar
• BELGHITI J, BENHAMOU JP, HOURY Set al.: Caustic sclerosing cholangitis. A complication of the surgical treatment of hydatid disease of the liver. Arch. Surg. (1986) 121:1162–1165.
   Google Scholar
• HOURY S, LANGUILLE 0, HUGUIER M et al.: Sclerosing cholangitis induced by formaldehyde solution injected into the biliary tree of rats. Arch. Surg. (1990) 125:1059–1061.
   Google Scholar
• BELGHITI J, PERNICENI T, KABBEJ Met al.: [Complication of perioperative sterilization of hydatid cysts of the liver. Apropos of 6 casesel. Chirurgie (1991) 117:343-346. French.
   Google Scholar
• ISHII M, MIYAZAKI Y, YAMAMOTO T: A case of drug-induced ductopenia resulting in fatal biliary cirrhosis. Liver (1993) 13:227–231.
   PubMedGoogle Scholar
• CICOGNANI C, MALAVOLTI M, MORSELLI-LABATE AM, SAMA C, BARBARA L: Flutamide-induced toxic hepatitis: potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig. Dis. Sci. (1996) 41:2219–2221.
   PubMed Web of Science ®Google Scholar
• PIOTROWICZ A, POLKEY M, WILKINSON M: Ursodeoxycholic acid for the treatment of flucloxacillin-associated cholestasis. I Hepatol (1995) 22:119–120.
   Web of Science ®Google Scholar
• KALLINOWSKI B, THEILMANN L, ZIMMERMAN R, GAMS E, KOMMERELL B, STIEHL A: Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid. Transplantation (1991) 51:1128–1129.
   PubMed Web of Science ®Google Scholar
• BATALLER R, BRAGULAT E, NOGUE S et al.: Prolonged cholestasis after acute paraquat poisoning through skin absorption. Am. J. Gastroenterol (2000) 95:1340–1343.
   PubMed Web of Science ®Google Scholar
• KATSINELOS P, VASILIADIS T, XIARCHOS P et al.: Ursodeoxycholic acid (UDCA) for the treatment of amoxicillin-clavulunate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur. I Gastroenterol Hepatol (2000) 12:365–368.
   PubMed Web of Science ®Google Scholar
• WENGROWER D: Possible ticlopidine-induced cholestatic jaundice. Am. Fam. Med. (2000) 62:1258.
   Google Scholar
• HUNT CM, WASHINGTON K: Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology (1994) 107:1844–1847.
   PubMed Web of Science ®Google Scholar
• MERTENS PR, SCHONFELDER T, HANDT S et al.: Long-term extracorporeal bilirubin elimination: a case report on cascade resin plasma perfusion. Blood PuriE (1998) 16:341–348.
   PubMed Web of Science ®Google Scholar
• HUSTER D, SCHUBERT C, BERR F, MOSSNER J, CASA K: Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). J. Hepatol (2002) 37:413.
   PubMed Web of Science ®Google Scholar
• CHEN LK, HSIEH BH, CHEN WC, TSAI Si HOU MC: Ticlopidine-induced hepatitis. Zhorighua Yi Xue Za Zhi (Taipei) (2001) 64:59–63.
   PubMedGoogle Scholar
• ADAMS L, JEFFREY GP, DEBOER B, GARAS G: Ticlopidine-associated cholestatic hepatitis. Intern. Med. J. (2002) 32:359–360.
   PubMed Web of Science ®Google Scholar
• CASSIDY LJ, SCHUSTER BG, HALPARIN LS: Probable ticlopidine-induced cholestatic hepatitis. Ann. Phannacother. (1995) 29:30–32.
   PubMed Web of Science ®Google Scholar
• GRIECO A, VECCHIO FM, GRECO AV, GASBARRINI G: Cholestatic hepatitis due to ticlopidine: clinical and histological recovery after drug withdrawal. Case report and review of the literature. Eur. Gastroenterol Hepatol (1998) 10:713–715.
   PubMed Web of Science ®Google Scholar
• AMARO P, NUNES A, MACOAS F et al: Ticlopidine-induced prolonged cholestasis: a case report. Eur. I Gastroenterol Hepatol (1999) 11:673–676.
   PubMed Web of Science ®Google Scholar
• WILLENS HJ: Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. Am.J Ther. (2000) 7:317–318.
   PubMedGoogle Scholar
• BELLARY SV, ISAACS PET: Captopril and the liver. Lancet (1989) 2:514.
   PubMed Web of Science ®Google Scholar
• RAHMAT J, GELFAND RL, GELFAND MC, WINCHESTER JF, SCHREINER GE, ZIMMERMAN HJ: Captopril-associated cholestatic jaundice. Ann. Intern. Med. (1985) 102:56–58.
   PubMed Web of Science ®Google Scholar
• TODD E LEVISON D, FARTHING MJ: Enalapril-related cholestatic jaundice. J R. .Sc. Med. (1990) 83:271–272.
   PubMed Web of Science ®Google Scholar
• NUNES AC, AMARO P, MAC AS F et al: Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. Eur. J Gastroenterol Hepatol (2001) 13:279–282.
   PubMed Web of Science ®Google Scholar
• BATEY RG, HARVEY M: Cholestasis associated with the use of pravastatin sodium. Med. J. Aust. (2002) 176:561.
   PubMed Web of Science ®Google Scholar
• HARTLEB M, RYMARCZYK G, JANUSZEWSKI K: Acute cholestatic hepatitis associated with pravastatin. Am.J Gastroenterol (1999) 94:1388–1390.
   PubMed Web of Science ®Google Scholar
• KEITH T: The liver and lovastatin. Am.J Cardiol (2002) 89:1374–1380.
   PubMed Web of Science ®Google Scholar
• RIDRUEJO E, MANDO OG: Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J Hepatol (2002) 37:165–166.
   PubMed Web of Science ®Google Scholar
• BALLARE M, CAMPANINI M, CATANIA E, BORDIN G, ZACCALA G, MONTEVERDE A: Acute cholestatic hepatitis during simvastatin administration. Recenti Frog. Med. (1991) 82:233–235.
   PubMedGoogle Scholar
• JIMENEZ-ALONSO J, OSORIO JM, GUTIERREZ-CABELLO F, LOPEZ DE LA OSA A, LEON L, MEDIAVILLA GARCIA JD: Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves. Arch. Intern. Med. (1999) 159:1811–1812.
   PubMed Web of Science ®Google Scholar
• FARRELL GC: Hepatitis C, other liver disorders, and liver health. Maclennan and Petty, Sydney (2002):1–320.
   Google Scholar
• ROBERT IM: Troglitazone-associated hepatic failure. Ann. Intern. Med. (1999) 130:4.
   Google Scholar
• BONKOWSKY HL, AZAR R, BIRDS, SZABO G, BANNER B: Severe cholestatic hepatitis caused by thiazolidinediones. Dig. Dis. Li. (2002) 7:1632–1637.
   Google Scholar
• MAY LD, LEFKOWITCH JH, KRAM MT, RUBIN DE: Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann. Intern. Med. (2002) 136:449–452.
   PubMed Web of Science ®Google Scholar
• FORMAN LM, SIMMONS DA, DIAMOND RH: Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. (2000) 132:118–121.
   PubMed Web of Science ®Google Scholar
• AL-SALMAN J, ARJOMAND H, KEMP DG, MITTAL M: Hepatocellular injury in a patient receiving rosiglitazone. Ann. Intern. Med. (2000) 132:121–124.
   PubMed Web of Science ®Google Scholar
• CHITTURI S, FARRELL GC: Etiopathogenesis of non-alcoholic steatohepatitis. Schuh. Liver Dis. (2001) 21:27–41.
   PubMed Web of Science ®Google Scholar
• CHITTURI S, ABEYGUNASEKERA S, FARRELL GC et al.: NASH and insulin resistance: insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology (2002) 35:373–379.
   PubMed Web of Science ®Google Scholar
• MARCHESINI G, FORLANI G: NASH: from liver disease to metabolic disorders and back to clinical hepatology. Hepatology (2002) 35:497–499.
   PubMed Web of Science ®Google Scholar
• KAPLOWITZ N: Avoiding hepatic injury from drugs. Gastroenterology (1999) 117:759.
   PubMed Web of Science ®Google Scholar
• •Article of interest. Discusses contemporary issues of diagnosis and prevention.
   Google Scholar
• GRAHAM DJ, DRINKARD CR, SHATIN D, TSONG Y, BURGESS MJ: Liver enzyme monitoring in patients treated with troglitazone. JAMA (2001) 286:831–833.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN M, WAHINUDDIN S, KEW ST: Glibenclamide-induced chronic cholestasis simulating primary binary cirrhosis: a case report. Med. J. Malaysia (1996) 51:140–143.
   PubMedGoogle Scholar
• THOLAKANAHALLI VN, POTTI A, HRYWORTH MF: Glibenclamide-induced cholestasis. West. J. Med. (1998) 168:274–277.
   PubMedGoogle Scholar
• DEL-VAL A, GARRIGUES V, PONCE J, BENAGES R: Glibenclamide-induced cholestasis. I Hepatol (1991) 13:375.
   Web of Science ®Google Scholar
• WONGPAITOON V, MILLS PR, RUSSELL RI, PATRICK RS: Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy. Postgrad. Med. J. (1981) 57:244–246.
   PubMed Web of Science ®Google Scholar
• GUPTA R, SACHAR DB: Chlorpropamide-induced cholestatic jaundice and pseudomembranous colitis. Am.J Gastroenterol (1985) 80:381–383.
   PubMed Web of Science ®Google Scholar
• FRIER BM, STEWART WK: Cholestatic jaundice following chlorpropamide self-poisoning. Clin. Toxicol (1977) 11:13–17.
   PubMed Web of Science ®Google Scholar
• DOURAKIS SP, TZEMANAKIS E, SINANI C, KAFIRI G, HADZIYANNIS SJ: Gliclazide-induced acute hepatitis. Eur. I Gastroenterol Hepatol (2000) 12:119–121.
   PubMed Web of Science ®Google Scholar
• SAW D, PITMAN E, MAUNG M, SAVASATIT P, WASSERMAN D, YEUNG CK: Granulomatous hepatitis associated with glyburide. Dig. Dis. Sci. (1996) 41:322–325.
   PubMed Web of Science ®Google Scholar
• RYLEY NG, FLEMING KA, CHAPMAN RWG: Focal destructive cholangiopathy associated with amoxicilliniclavulanic acid (Augmentin). Hepatol (1995) 23:278–282.
   Web of Science ®Google Scholar
• RYAN J, DUDLEY F: Cholestatic hepatitis associated with clavulanic acid. Gut (1992) 33:1583.
   PubMed Web of Science ®Google Scholar
• LARREY D, VIAL T, MICALEFF A et al.: Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut (1992) 33:368–371.
   PubMed Web of Science ®Google Scholar
• HEBBARD GS, SMITH KG, GIBSON PR, BHATAL PS: Augmentin-induced jaundice with a fatal outcome. Med. J. Aust. (1992) 156:285–286.
   PubMed Web of Science ®Google Scholar
• REDDY KR, BRILLIANT P, SCHIFF ER: Amoxycillin-clavulanate potassium-associated cholestasis. Gastroenterology (1989) 96:1135–1141.
   PubMed Web of Science ®Google Scholar
• ECKSTEIN RE DOWSETT JF, LUNZER MR: Flucloxacillin-induced liver disease: histopathological findings at biopsy and autopsy. Pathology (1993) 25:223–228.
   PubMed Web of Science ®Google Scholar
• KOEK GH, STRICKER BH, BLOK AP, SCHALM SW, DESMET VJ: Flucloxacillin-associated hepatic injury. Liver (1994) 14:225–229.
   PubMedGoogle Scholar
• PRESTI ME, JANNEY CG, NEUSCHWANDER-TETRI BA: Nafcillin-associated hepatotoxicity. Report of a case and review of the literature. Dig. Dis. Sci. (1996) 41:180–184.
   PubMed Web of Science ®Google Scholar
• DERBY LE, JICK H, HENRY DA, DEAN AD: Erythromycin-associated cholestatic hepatitis. Med. J. Aust. (1997) 158:217–218.
   Google Scholar
• LLOYD-STILL JD, SHERMAN JO, BOGGS J, DEMERS LM: Erythromycin estolate hepatotoxicity. Am. J. Dis. Child (1978) 132:320.
   PubMedGoogle Scholar
• DIEHL AM, LATHAM P, BOINOTT JK, MANN J, MADDREY WC: Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases. Am. J. Med. (1984) 76:931–934.
   Google Scholar
• BACHMAN BA, BOYD WP Jr, BRADY PG: Erythromycin ethylsuccinate-induced cholestasis. Am. J. Gastroenterol (1982) 77:397–400.
   PubMed Web of Science ®Google Scholar
• DE ESCALANTE B, SAMPEDRO JA, ZABALA S, GRACIA P: [Cholestatic hepatitis caused by erythromycin proprionatel. Ann. Med. Interna (1990) 7:656. Spanish.
   Google Scholar
• LARREY D, AMOUYAL G, DANAN G et al: Prolonged cholestasis after troleandomycin-induced acute hepatitis. Hepatol (1987) 4:327–329.
   Web of Science ®Google Scholar
• GEUBEL A1 NAKAD A, RAHIER J, DIVE C: Prolonged cholestasis and disappearance of interlobular bile ducts following chlorpropamide and erythromycin ethylsuccinate. Case of drug interaction? Liver (1988) 8:350–353.
   Google Scholar
• LAZARCZYK DA, DUFFY MC: Erythromycin-induced primary biliary cirrhosis. Dig. Dis. Li. (2000) 45:1115–1118.
   PubMed Web of Science ®Google Scholar
• AGGARWAL A, GURKA J: Probable ciprofloxacin-induced cholestasis. Aust. NZ J. Med. (1995) 25:541–542.
   PubMedGoogle Scholar
• SHERMAN 0, BEIZER JL: Possible ciprofloxacin-induced acute cholestatic jaundice. Ann. Pharmacother. (1994) 28:1162–1164.
   PubMed Web of Science ®Google Scholar
• SAMARASINGHE DA, GEORGE J, FARRELL GC: Drug-induced liver disease. In: Current Hepatology (Vol. 14). Gitnick G (Ed.), Mosby, St Louis, MO (1994):117–167.
   Google Scholar
• •Article of interest. Comprehensive review of DILD.
   Google Scholar
• LANA R, NUNEZ M, MENDOZA JL, SOIANO V: [Rate and risk factors of liver toxicity in patients receiving antiretroviral therapol. Med. Clin. (Barc) (2001) 117:607-610. Spanish.
   Google Scholar
• VERDON R, SIX M, ROUSSELOT P, Bazin C et al: Efavirenz-induced acute eosinophilic hepatitis. J. Hepatol (2001) 34:783–785.
   PubMed Web of Science ®Google Scholar
• JOHNSON S, BARABOUTIS JG, SHA BE et al.: Adverse effects associated with use of nevirapine in HIV post-exposure for two healthcare workers. JAMA (2000) 284:2722-2723. Letter.
   Google Scholar
• O'BEIRNE JP, CAIRNS SR: Cholestatic hepatitis in association with celecoxib. Br Med. J. (2001) 323:23.
   PubMed Web of Science ®Google Scholar
• JONES B: Celecoxib cholestasis. Med. J. Aust. (2001) 174:368. Letter.
   Google Scholar
• GALAN MV, GORDON SC, SILVERMAN AL: Celecoxib-induced cholestatic hepatitis. Ann. Intern. Med. (2001) 134:254.
   PubMed Web of Science ®Google Scholar
• NACHIMUTHU S, VOLFINZON L, GOPAL L: Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad. Med. J. (2001) 77:548–550.
   PubMed Web of Science ®Google Scholar
• MATHEWS JD, RILEY MD, FEJO L et al: Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med. J. Aust. (1988) 148:548–555.
   PubMed Web of Science ®Google Scholar
• RUSSMAN S, LAUTERBURG BH, HELBLING A: Kava hepatotoxicity. Ann. Intern. Med. (2001) 135:68-69. Letter.
   Google Scholar
• STEDMAN C: Herbal hepatotoxicity. &min. Liver Dis. (2002) 22:195–206.
   PubMed Web of Science ®Google Scholar
• ••Article of considerable interest. Recentexcellent review of CAM and herbal toxicity affecting the liver.
   Google Scholar
• SHEIKH NM, PHILEN RM, LOVE LA: Chaparral-associated hepatotoxicity. Arch. Intern. Med. (1997) 157:913–919.
   PubMed Web of Science ®Google Scholar
• SMITH BC, DESMOND PV: Acute hepatitis induced by ingestion of the herbal medicine chapparal. Aust. NZ J. Med. (1993) 23:526.
   PubMedGoogle Scholar
• •Article of interest. Good discussion of chapparal hepatoxicity.
   Google Scholar
• BENNINGER J, SCHNEIDER HT, SCHUPPAN D, KIRCHNER T, HAHN EG: Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology (1999) 117:1234–1237.
   PubMed Web of Science ®Google Scholar
• WHITING PW, CLOUSTON A, KERLIN P: Black cohosh and other herbal remedies associated with acute hepatitis. Med. I Aust. (2002) 177:440–443.
   PubMed Web of Science ®Google Scholar
• SATO H, GOTO W, YAMAMURA J et aL: Therapeutic basis of glycyrrhizin on chronic hepatitis. Antiviral Res. (1996) 30:171–177.
   PubMed Web of Science ®Google Scholar
• PARK GJ, MANN SP, NGU MC: Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multillorum. I Gastroenterol Hepatol (2001) 16:115–117.
   PubMed Web of Science ®Google Scholar
• MCRAE CA, AGARWAL K, MUTIMER D, BASSEDINE MF: Hepatitis associated with Chinese herbs. Eur. I Gastroenterol Hepatol (2002) 14:559–562.
   PubMed Web of Science ®Google Scholar
• KANE JA, KANE SP, JAIN S: Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut (1995) 36:146–147.
   PubMed Web of Science ®Google Scholar
• MADDREY WC: Isoniazid-induced liver disease. Semin. Liver Dis. (1981) 1:129–133.
   PubMedGoogle Scholar
• CHIEN RN, YANG LJ, LIN PY, LIAW YF: Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology (1997) 25:103–107.
   PubMed Web of Science ®Google Scholar
• KROMANN-ANDERSEN H, PEDERSEN A: Reported adverse reactions to and consumption of nonsteroidal anti-inflammatory drugs in Denmark over a 17-year period. Dan. Med. Bull. (1988) 35:187–192.
   PubMed Web of Science ®Google Scholar
• GARCIA RODRIGUEZ LA, STRICKER BH, ZIMMERMAN HJ: Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch. Intern. Med. (1996) 156:1327–1332.
   PubMed Web of Science ®Google Scholar